Background: Patient self-report is a practical method for measuring adherence, but little is known about its optimal use. Objectives: To examine the retest reliability and predictive validity of 3 different types of self-report adherence measures among patients with common chronic illnesses. Research Design: Correlation and regression analyses of data from an ongoing randomized controlled trial. Subjects: Patients (N ϭ 415) aged Ն40 years recruited from a primary care network with arthritis, asthma, chronic lung disease, congestive heart failure, depression, and/or diabetes mellitus, plus impairment in Ն1 basic activity and/or a score of Ն4 on the 10-item Center for Epidemiologic Studies Depression Scale. Measures: Self-report adherence (administered variously at baseline, 2, 4, and 6 weeks, and 6 months): number of pills taken/number of pills prescribed (PT/PP), using 1-7 days recall, and global reports of medication adherence and overall adherence tendencies. Sixmonth functional outcomes: Health Assessment Questionnaire (HAQ) and Short Form-36 (SF-36). Results: Correlation coefficients among contemporaneously administered 1-7 days PT/PP measures were Ն0.78. Correlations among PT/PP measures and global adherence measures, and among PT/PP measures at 2 and 4 weeks, ranged from 0.11 to 0.54. PT/PP measures using Ն3-4 days recall significantly predicted adjusted 6-month HAQ but not SF-36 score. Conclusions: Self-report PT/PP and general medication adherence measures tap different behavioral constructs. Self-reported PT/PP at a given point in time is not necessarily representative of medication adherence over time. Among chronically ill patients, 3-4 days recall of PT/PP yield adherence estimates, which are practically as reliable and valid as longer intervals and which predict functional outcomes.
M edication adherence has been associated in some (but not all [1] [2] [3] ) studies with improved chronic illness outcomes. 4 Indeed, the act of adhering to a medication regimen seems to have health benefits that are in some cases independent of medication effects. [5] [6] [7] Optimal measurement of medication adherence remains an important issue for clinical research, but no gold standard measure of medication adherence currently exists. 8 A number of measurement approaches are commonly used, including subjective patient self-reports and objective methods such as pill counts, electronic pill bottle monitoring (EPBM), prescription tracking in administrative databases, and blood level monitoring. 9 Some studies suggest that self-report measures systematically yield higher adherence estimates than objective measures, 10 because of social desirability and memory biases. 11 Yet in a meta-analysis, self-report adherence estimates were higher than objective assessments only for within study comparisons, while for across study comparisons, self-report was associated with lower estimates of adherence than objective measures. 8 Objective adherence measures also have some important drawbacks. EPBM and pill counts may convey to subjects that they are not trusted, engendering resentment and undermining chronic illness interventions that are grounded in self-efficacy theory. 10 Objective measures may also lead to surreptitious discarding of medication, leading to inflated adherence estimates. 12 EPBM caps are expensive, 10 and because each medication requires its own monitored bottle, participants cannot use adherence-enhancing pill organizers, potentially leading to recruitment of nonrepresentative study samples and falsely decreased adherence estimates. 10, 13, 14 Finally, prescription databases provide indirect estimates of adherence which may correlate poorly with estimates by other methods. 10 Given these drawbacks of objective measures, patient self-report emerges as a practical approach to estimating medication adherence, and one which reflects the individual perspectives of chronically ill patients. 14, 15 There are 3 general types of self-report measures: (1) general adherence tendencies; (2) medication taking habits; and (3) specific quantities of pills taken over an identified period of time, expressed as a proportion ͓number of pills taken/number of pills prescribed (PT/PP)͔. Much remains to be learned about each type of measure. Few studies use multiple measures, however, so there is little data to examine their relative reliability and validity, 16 and their comparative predictive validity regarding functional chronic illness outcomes in adults has not been established. 4 In addition, no research has yet identified the recall interval that best balances measurement reliability and feasibility of data collection. 15 Only 1 study (involving adherence to antiretroviral medications in patients with HIV infection) has reported the correlation (r ϭ 0.81, P Ͻ 0.001) between PT/PP over a shorter (1-day) versus a longer (7-day) recall period. 17 Although relatively longer periods might be expected to yield even more reliable estimates, in studies of chronically ill patients taking numerous medications, 18 the data collection burden on research staff and subjects can be substantial.
This report begins to fill these important gaps in the literature. We explored the reliability and validity of 3 different kinds of self-report medication adherence measuresrecall of specific quantities of PT/PP over 1-day through 7-day recall intervals, the Self Reported Medication-Taking Scale (SRMTS), 19 and the Medical Outcomes Study (MOS) General Adherence measure. 20 We studied a mixed diagnosis population of chronically ill individuals taking multiple daily medications, and our primary outcomes were generic functional measures that were broadly applicable across diagnoses. We examined the following research questions: (1) What are the correlations among PT/PP adherence recalled at 1-7 days? (2) What are the correlations between PT/PP measures and the 2 more general self-report adherence measures? (3)What are the test-retest reliability correlations between PT/PP measures assessed at 2 weeks and 4 weeks after baseline? (4) What are the correlations among the various adherence measures and key contemporaneously recorded covariates such as education, age, health status, depression symptoms, and personality? (5) Do the adherence measures predict 6-month functional outcomes?
METHODS

Study Setting, Subject Recruitment, and Randomization
Analyses were conducted on data collected in an ongoing randomized controlled trial (RCT) of home-delivered variants of the Stanford Chronic Disease Self-Management Program. 21, 22 The overall goals of the program are to determine whether in-home and/or telephone adaptations of the program enhance self-efficacy and improve outcomes for chronically ill people. Details regarding the adaptations have been described previously, 23 and further information is available from the authors.
A convenience sample of participants was recruited from the 12 offices in the University of California Davis (UCD) Primary Care Network, which span a 50-mile radius around the Sacramento, California, metropolitan area. Patients in these offices receive primary care from family physicians or general internists. The UCD Institutional Re-view Board approved the study protocol. A study nurse administered the baseline questionnaire to all subjects at a home visit. Telephone interviewers administered follow-up study questionnaires during (2 and 4 weeks), immediately following (6 weeks), and 6 months after completion of the intervention.
Measures Adherence
General adherence tendencies were measured at baseline using the 5-item MOS General Adherence scale (Cronbach's ␣ reliability ϭ 0.87 in this sample). 20 Using a 6-point Likert response scale, respondents rated how often they were able to follow their doctor's overall treatment plans and suggestions. Possible scores ranged from 6 to 30, with higher scores indicating better adherence. Medication taking habits were measured at baseline using the 4-item SRMTS (Cronbach's ␣ ϭ 0.56 in this sample). 19 Subjects responded to yes/no questions asking whether they ever engaged in suboptimal medication adherence behaviors, such as being careless with their medicines. Possible scores ranged from 0 to 4, with higher scores indicating less optimal medication adherence behaviors.
Finally, a detailed questionnaire, modified from Arnsten et al, 17 was administered at 2 and 4 weeks and at 6 months, to solicit a detailed pill-taking history for the preceding week. For each medication being taken on the day of data collection, participants were asked a series of questions to clarify how many pills per day they were asked to take by their doctor and how many they actually took. Each question solicited adherence information in a slightly different manner, leading finally to completion of a 7-day grid for each medication containing PT/PP for each day in the 7 days preceding (not counting) the day of data collection. For each participant, the data from the weekly grids (all medications combined) were used to derive PT/PP for 1, 2, 3, 4, 5, 6, and 7 days.
Six-Month Functional Outcomes
Basic functional ability was measured using the 20 task-oriented items on the Health Assessment Questionnaire (HAQ). 24 
Other Measures
Beyond basic sociodemographics (eg, age, gender), 2 remaining measures were included. Subjects were administered the 10-item version of the Center for Epidemiologic Studies Depression (CES-D) scale at baseline (Cronbach's ␣ ϭ 0.68). 26 The possible range of scores was 0 -30, with higher scores indicating more depressive symptoms. Finally, Medical Care • Volume 46, Number 11, November 2008 Self-Report Adherence in Chronic Illness at baseline, subjects completed the NEO-five factor inventory (NEO-FFI), a 60-item inventory designed to assess the domains of the "Five Factor Model" of personality: neuroticism, extraversion, openness to experience, agreeableness, and conscientiousness. 27 Based on prior research, 28 and our interest in adherence, analyses focused on the Conscientiousness subscale (Cronbach's ␣ ϭ 0.82).
Analyses
Data were analyzed using STATA (version 10.0, Stata-Corp, College Station, TX). Correlations were examined both with Pearson's and Spearman's correlations. The latter was done to address the nonlinearity of the adherence measures (most severely right skewed). The results using Spearman correlations were essentially the same as those using Pearson correlations and are not presented. A regression analysis predicting HAQ score at 6 months was performed, with the following entered into the model as covariates: age in years; gender, minority status (non-Hispanic white, or other), education (Ͻ12, 12, and Ͼ12 years); chronic medical condition, study group, baseline HAQ, Conscientiousness, PCS-36 and MCS-36 scores; and week 2 SRMTS, MOS General Adherence, and PT/PP. No significant collinearity was observed among covariates, with variance inflation factors of 2.3 or less noted.
RESULTS
Participant Characteristics
Of the 415 participants, 378 (91.1%) provided PT/PP information at 2 weeks and 353 (85.1%) provided complete 6-month follow-up information. Mean participant age was 60.3 (SD 11.3), 77.3% were women, 82.9% were non-Hispanic white, 85.1% had at least some college education, and 78.5% had private health insurance. Subjects averaged 1.9 (SD 1.0) self-reported chronic conditions. Table 1 summarizes participant health status, adherence, and covariate scores. Health status scores were notably lower than population averages, particularly for the PCS-36 and HAQ. Only 28 subjects (7.4%) reported taking no medications. Although only 7 days recall PT/PP information is presented in Table 1 , the means, SDs, and ranges for 1-6 days recall PT/PP measures were quite similar (details available from the authors).
Research Question 1-Correlations Among Contemporaneously
Administered Pill-Taking Measures (PT/PP). All but 2 of these correlations were significant. Correlation coefficients Table 2 ). Of note, the correlations between 7-day and 1-day recall measures were stronger than those between the two 1-day recall measures. Correlations increased as the number of days recall increased, though gains above 3-4 days were modest.
Research Question 4 -Correlations Among Medication
Adherence Measures, Health Status, and Covariates. Correlations among the PT/PP measures and the NEO-FFI Conscientiousness scale were as strong as correlations among the PT/PP and the 2 general adherence measures (Table 3) . Furthermore, correlations among the PT/PP measures and 2 mental health measures (MCS-36 and CES-D) were greater than those among the PT/PP and the 2 more general adherence measures; higher self-reported adherence was associated with better mental health.
Research Question 5-Ability of Self-Report Adherence
Measures to Predict 6-Month Functional Outcomes. There were no significant relationships between any of the 2-week PT/PP adherence measures and 6-month PCS-36 or MCS-36 scores (Table 4 ). However, PT/PP measured at 2 weeks (using 4-day recall) predicted adjusted 6-month HAQ scores. No substantive gain in predictive ability beyond use of 3-4 days recall was realized with inclusion of other variables in the model. The MOS General Adherence, SRMTS, and Conscientiousness measures did not predict 6-month HAQ scores.
DISCUSSION
The findings related to each of our research questions have important implications regarding the reliability and validity of self-report measures of medication adherence in mixed populations of chronically ill individuals taking multiple daily medications.
In our RCT, the mean time required for data collection personnel to gather PT/PP data per encounter was 15 minutes (range, 7-27 minutes), and the PT/PP items were part of a much lengthier study questionnaire. In the context of this considerable data collection burden, our findings of only modest gains in correlation strength with increasing days of PT/PP recall suggest using 3-4 days of recall may provide an optimal balance of measurement reliability and data collection feasibility in patients with chronic illness. However, replication of these findings is needed before firm conclusions can be drawn.
Of note, the correlation between the 1-day PT/PP measure and the 7-day PT/PP measure was 0.78. Both were modified from measures developed by Arnsten et al, 17 who found a similar correlation of 0.81 in a study measuring antiretroviral medication adherence in HIV-infected individuals. Although clearly not as strong as the very high (Ͼ0.9) The correlations observed among PT/PP and general adherence measures were modest, indeed little different than correlations among the PT/PP and nonadherence measures (NEO-FFI, MCS-36, and CES-D). These findings suggest that the PT/PP and more general adherence measures each tap somewhat different constructs. It may therefore be advisable to include a representative measure from each of these selfreport categories in studies of medication adherence in chronically ill people, to obtain a more comprehensive, nuanced view of adherence behaviors in such individuals. 29 However, how best to reconcile the different estimates of adherence yielded by different measures within a study remains unclear.
The finding that correlations among the 2-week and either 4-week or 6-month PT/PP measures were considerably weaker than correlations among the contemporaneously administered 2-week PT/PP measures suggests that, in general, there is poor stability of PT/PP adherence estimates over time in chronically ill individuals taking multiple medications. At the least, these findings suggest medication adherence estimates obtained by patient self-report at any given point in time may not necessarily be representative of medication adherence over time. Further work is needed to investigate the implications of these findings, but in the meantime, researchers should be aware that the timing of administration of adherence measures may significantly influence the adherence estimates.
Finally, better PT/PP adherence measured at 2 weeks was associated with improved adjusted HAQ scores at 6 months. Although self-reported medication adherence has been correlated in previous studies with a number of chronic illness outcomes, 4 it has not, to our knowledge, been shown to predict generic functional outcomes. Unfortunately, our analyses do not allow us to distinguish whether the improvement occurred via direct "biologic" medication effects, or via positive expectations creating to a "healthy adherer" effect. [5] [6] [7] Future studies designed specifically to examine this intriguing clinical question seem warranted.
This study had a number of strengths, including the use of prospectively collected data from a RCT and the use of previously validated medication adherence, functional outcome, and covariate measures. Our main study limitation was purposeful: we used only self-report adherence measures because we felt they were the only ones that meshed well with the theoretical grounding (self-efficacy theory) and overall aims of our RCT. As noted previously, however, selfreport measurement of medication adherence has some limitations, including a tendency in some (but not all 8 ) studies to yield higher estimates of adherence than other measurement approaches. 10, 11 Although it is unclear whether over-reporting of adherence occurred in our study, the apparent differential prompting of favorable self-report adherence responses by study group does provide indirect evidence of overreporting.
Another limitation is that our study population was comprised of a convenience sample of relatively high functioning individuals with several common chronic conditions, most of whom were white, female, relatively well-educated, and had private health insurance. Thus, our results may not be readily generalizable to other groups. We also had research personnel administer questionnaires to collect patient selfreport data. We did not use subject self-completed measures, such as daily medication taking diaries, 10 because of concerns about potentially low rates of completion and large amounts of missing data. 30 Self-completed measures may have yielded findings different from these. 31 A final limitation was that the reliabilities for several of our measures (SRMTS ϭ 0.56, HAQ ϭ 0.65, CES-D ϭ 0.68) were marginal in this sample.
In conclusion, the key implications of our findings for self-report medication adherence measurement in mixed diagnosis populations of chronically ill individuals are as follows: (1) specific pill taking self-report medication adherence measures and those concerning more general adherence behaviors each seem to tap different yet potentially important behavioral constructs; (2) PT/PP recall over 3-4 days may yield adherence estimates that are practically as reliable and valid as those collected over longer recall intervals but are less burdensome to obtain; (3) 1-day recall PT/PP adherence, because it correlates moderately strongly (0.78 in our study) with 7-day recall PT/PP adherence, may offer an attractive option to estimating medication adherence in resource-poor environments; (4) 2-week test-retest of PT/PP recall is modest (all correlations Յ0.49), suggesting that 1-point-in-time assessment of adherence has limited reliability; and (5) PT/PP adherence measured at 2 weeks was associated with 6-month HAQ scores, suggesting the potential importance of medication adherence as a predictor of health outcomes. Our study is the first to begin to fill these and other gaps in the literature regarding medication adherence measurement in chronically ill individuals. Future studies designed to explore each of these intriguing outcomes seem warranted.
